natgillin/translations-raw huggingface dataset:
DEX 40 mg/day on days 1-4 and 11-14, alternated with MTX 1 g/ m2 i.v.
DEX 40 mg/danna dane 1-4 i 11-14, izmjenjivano sMTX 1 g/m2 i.v. (24 h), dan 1, Ara-C 1 g/m2 i.v. (2 h, svakih 12 h), dani 2-3 (ukupno 8 ciklusa)
Use in adults
Primjena uodraslih osoba
Induction therapy II
Konsolidacijska terapija 2
NAME OF MEDICINAL PRODUCT Imatinib Accord 100 mg film-coated tablets Imatinib Accord 400 mg film-coated tablets
Imatinib Accord 100 mg filmom obložene tablete Imatinib Accord 400 mg filmom obložene tablete
BM = bone marrow, PB = peripheral blood Cytogenetic response criteria: A major response combines both complete and partial responses: complete (0% Ph+ metaphases), partial (1-35%) 3 Complete cytogenetic response confirmed by a second bone marrow cytogenetic evaluation performed at least one month after the initial bone marrow study.
* p<0,001, Fischerov egzaktni test ** postotci molekularnog odgovora se temelje na dostupnim uzorcima Kriteriji hematološkog odgovora (svi se odgovori moraju potvrditi nakon ≥4 tjedna): WBC <10 x 109/l, trombociti < 450 x 109/l, mijelociti+metamijelociti <5% u krvi, nema blasta i promijelocita u krvi, bazofili < 20%, nema ekstramedularne zahvaćenosti Kriteriji citogenetskog odgovora: potpun (0% Ph+ metafaza), djelomičan (1-35%), manji (36-65%) ili minimalan (66-95%).
Your doctor may decide to increase the dose to 400 mg, to be taken as 4 tablets of 100 mg or one tablet of 400 mg once a day, depending on how you respond to treatment.
Ovisno o tome kako reagirate na liječenje, liječnik može odlučiti povećati dozu do 400 mg, a uzimaju se 4 tablete od 100 mg ili jedna tableta od 400 mg jednom dnevno.
SPECIAL STORAGE CONDITIONS For PVC/PVdC/Alu blisters Do not store above 30C.
POSEBNE MJERE ČUVANJA Za PVC/PVdC/Alu blistere
CP 1 g/ m2 i.v.
CP 500 mg/m2 i.v.(1 h) dan 1;
Tumour haemorrhage/tumour necrosis* Immune system disorders Not known
Nepoznato Tumorsko krvarenje/tumorska nekroza* Poremećaji imunološkog sustava Nepoznato Anafilaktički šok* Poremećaji krvi i limfnog sustava Vrlo često
The recommended dose of Imatinib Accord is 100 mg/day for adult patients with HES/CEL.
Za odrasle bolesnike s HES/KEL-om preporučena doza Imatinib Accorda iznosi 100 mg/dan.
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 100 mg imatinib (as mesilate)
NAVOĐENJE DJELATNE(IH) TVARI Jedna filmom obložena tableta sadrži 100 mg imatiniba (u obliku imatinibmesilata).
Brownish orange, round, biconvex, film-coated tablets, debossed on one side with ‘IM' and ‘T1' on either side of breakline and plain on the other side.
Smećkastonarančaste, okrugle, bikonveksne filmom obložene tablete s utisnutom oznakom „IM“ na jednoj strani razdjelne crte i „T1“ na drugoj strani razdjelne crte te bez oznaka na drugoj strani tablete.
6-MP (75 mg/m2/day, PO): days 11-56 (Withhold 6-MP during the
6-MP (75 mg/m2/dan, p.o.): dani 11-56 (Uskratiti 6-MP tijekom 6-10 dana kranijalne iradijacije dana 1, ciklusa 5. Započeti 6-MP 1-og dana nakon završetka kranijalne iradijacije.)
If you are being treated for Ph-positive ALL The starting dose is 600 mg to be taken as 6 tablets of 100 mg or one tablet of 400 mg plus 2 tablets of 100 mg once a day.
Početna doza je 600 mg, koja se uzima kao 6 tableta od 100 mg ili kao jedna tableta od 400 mg te 2 tablete od 100 mg jednom na dan.
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 400 mg imatinib (as mesilate)
NAVOĐENJE DJELATNE(IH) TVARI Jedna filmom obložena tableta sadrži 400 mg imatiniba (u obliku imatinibmesilata).
Etoposide 250 mg/ m2 i.v.
Etopozid 250 mg/m2 i.v. (1 h) dani 4-5;
Prednisone 60 mg/m2 oral, days 1-7, 15-21; IDA 9 mg/m2 oral, days 1-28;
Prednizon 60 mg/m2peroralno, dani 1-7, 15-21;
VCR 2 mg i.v., days 6, 13, 20;
I DEX 10 mg/m2peroralno, dani 1-5; VCR 2 mg i.v., dani 6, 13, 20;
• Severe headache, weakness or paralysis of limbs or face, difficulty speaking, sudden loss of consciousness (signs of nervous system problems such as bleeding or swelling in skull/brain).
• teška glavobolja, slabost ili oduzetostudova ili lica, otežan govor, iznenadni gubitak svijesti
aANC < 0.5x109/1 and/or platelets < 10 x 109/1
aABN <0,5 x 109/l i/ili trombociti <10 x 109/l
Consolidation therapy DEX 10 mg/ m2oral, days 1-5; Vindesine 3 mg/ m2 i.v., day 1;
DEX 10 mg/m2peroralno, dani 1-5; CP 200 mg/m2 i.v., dani 3-5;
Brownish orange, oval shaped, biconvex, film-coated tablets, debossed on one side with ‘IM' and ‘T2' on either side of breakline and plain on the other side.
Smećkastonarančaste, ovalne, bikonveksne filmom obložene tablete s utisnutom oznakom „IM“ na jednoj strani razdjelne crte i „T2“ na drugoj strani razdjelne crte te bez oznaka na drugoj strani tablete.
• Feeling sick (nausea), being sick (vomiting), diarrhoea or indigestion.
• mučnina, povraćanje, proljev ili probavne smetnje.
Imatinib Accord is indicated for the treatment of
Accord je indiciran za liječenje
Pericarditis*, cardiac tamponade* Vascular disorders4
Periorbitalni edem, dermatitis/ekcem/osip
3) [95% CI]
Potpuni (Potvrđeni3) [95% CI]
Common
Djelomični
Haematological experts in the management of this disease should supervise the therapy throughout all phases of care.
Za odrasle bolesnike s Ph+ ALL-om preporučena doza imatiniba iznosi 600 mg/dan.Specijalisti hematolozi uključeni u liječenje ove bolesti trebaju nadzirati terapiju kroz sve faze liječenja.
One large, open-label, multicentre, international randomised phase III study has been conducted in patients with newly diagnosed Ph+ CML.In addition, children and adolescents have been treated in two phase I studies and one phase II study.
Osim toga, djeca i adolescenti liječeni su u dva ispitivanja faze I i jednom ispitivanju faze II.
NAME OF THE MEDICINAL PRODUCT Imatinib Accord 100 mg film-coated tablets imatinib
Imatinib Accord 100 mg filmom obložene tablete imatinib
NAME OF THE MEDICINAL PRODUCT Imatinib Accord 400 mg film-coated tablets imatinib
Imatinib Accord 400 mg filmom obložene tablete imatinib
• For PVC/PVdC/Alu blisters Do not store above 30C.
• Za PVC/PVdC/Alu blistere
(3 h, q 12 h), days 1-3; Vincristine 2 mg i.v., days 4, 11;
Hiper-CVAD režim: CP 300 mg/m2 i.v. (3 h, svakih 12 h), dani 1-3; Vinkristin 2 mg i.v., dani 4, 11;
If you are being treated for MDS/MPD The starting dose is 400 mg to be taken as 4 tablets of 100 mg or one tablet of 400 mg once a day.
Početna doza je 400 mg, koja se uzima kao 4 tablete od 100 mg ili 1 tableta od 400 mg jednom na dan.
Daunorubicin 60 mg/ m2 i.v.
Vindezin 3 mg/m2 i.v., dan 1;
Inductionconsolidation therapy
Studija AUS01 Indukcijskokonsolidacijska terapija
Molecular response**
gastrična antralna vaskularna ektazija (GAVE)*
The recommended dosage of Imatib Accord is 400 mg/day for adult patients in chronic phase CML.
Za odrasle bolesnike u kroničnoj fazi KML-a preporučena doza Imatinib Accorda iznosi 400 mg/dan.
Vertigo, tinnitus, hearing loss
Manje često Vrtoglavica, tinitus, gubitak sluha Srčani poremećaji
• Stomach pain with feeling sick (nausea).
• bol u trbuhu s mučninom.
Ara-C 2x 2 g/ m2 i.v.
Ara-C 2x 2 g/m2 i.v. (3 h, svakih 12 h), dan 5
Elderly
sepsa
MTX 12 mg intrathecal, day 1 Remission induction DEX 10 mg/ m2 oral, days 6-7, 13-16;
Indukcija remisije DEX 10 mg/m2peroralno, dani 6-7, 13-16; VCR 1 mg i.v., dani 7, 14;
16 December 2016 EMA/822770/2016 EMEA/H/C/004023
EMA/822770/2016 EMEA/H/C/004023
On 16 November 2016, Gedeon Richter Plc officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Efgratin, for reducing neutropenia.
Dana 16. studenoga 2016., tvrtka Gedeon Richter Plc službeno je obavijestila Odbor za lijekove za humanu uporabu (CHMP) kako želi povući svoj zahtjev za odobrenje za stavljanje u promet lijeka Efgratin za smanjenje neutropenije.
What is Efgratin?
Što je Efgratin?
This means that Efgratin was intended to be highly similar to a biological medicine (the ‘reference medicine') already authorised in the European Union called Neulasta.
To znači da je Efgratin trebao biti vrlo sličan biološkom lijeku („referentnom lijeku”) koji je već odobren u Europskoj uniji (EU) pod nazivom Neulasta.
Efgratin was developed as a ‘biosimilar' medicine.
Efgratin je razvijen kao biosličan lijek.
The company presented results of studies in healthy people designed to show that Efgratin is highly similar to its reference medicine Neulasta in terms of chemical structure, purity, the way it works and how the body handles the medicine.
Tvrtka je predočila rezultate ispitivanja u zdravih ljudi koja su provedena kako bi se dokazalo da je Efgratin vrlo sličan svojem referentnom lijeku Neulasta u smislu kemijske strukture, čistoće, načina djelovanja i načina na koji tijelo podnosi lijek.
A further study in patients receiving cancer medicines compared the safety and effectiveness of Efgratin and Neulasta.
U dodatnom ispitivanju, koje je uključivalo bolesnike koji su dobivali lijekove za liječenje raka, provedena je usporedba sigurnosti i učinkovitosti lijekova Efgratin i Neulasta.
What was Efgratin expected to be used for?
Za što se Efgratin trebao koristiti?
Withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim)
Povlačenje zahtjeva za izdavanje odobrenja za stavljanje u promet lijeka Efgratin (pegfilgrastim)
Neutropenia is a side effect of certain cytotoxic (cell-killing) cancer treatments because the treatments also kill white blood cells.
Neutropenija je nuspojava određenih citotoksičnih (ubijanje stanica) načina liječenja raka jer se takvim liječenjem ubijaju i bijele krvne stanice.
How does Efgratin work?
Kako djeluje Efgratin?
The active substance in Efgratin, pegfilgrastim, consists of filgrastim that has been 'pegylated' (attached to a chemical called polyethylene glycol).
Djelatna tvar u lijeku Efgratin, pegfilgrastim, sastoji se od filgrastima koji je „pegiliran” (spojen s kemijskom tvari koja se naziva polietilen glikol).
The company informed the CHMP that there are no ongoing clinical trials or compassionate-use programmes for Efgratin.
Tvrtka je obavijestila CHMP da nema kliničkih ispitivanja ili programa milosrdnog davanja lijeka Efgratin koji su u tijeku.
Withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim) EMA/822770/2016
(pegfilgrastim) EMA/822770/2016
Efgratin is a medicine that contains the active substance pegfilgrastim, which stimulates the production of neutrophils (a type of white blood cell that fights infections).
Efgratin je lijek koji sadrži djelatnu tvar pegfilgrastim koja potiče stvaranje neutrofila (vrsta bijelih krvnih stanica koje se bore protiv infekcija).
Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Efgratin could not have been approved for reducing neutropenia.
Na temelju pregleda podataka te odgovora tvrtke na popise pitanja CHMP-a, u trenutku povlačenja CHMP je izrazio svoju zabrinutost te je njegovo privremeno mišljenje bilo da nije moguće dati odobrenje za lijek Efgratin za smanjenje neutropenije.
Efgratin was to be used to reduce the duration of neutropenia and the occurrence of febrile neutropenia (neutropenia with fever).
Lijek Efgratin trebao se primjenjivati za smanjenje trajanja neutropenije i pojave febrilne neutropenije (neutropenija praćena vrućicom).
The CHMP was concerned that study results had not shown that Efgratin was handled by the body in the same way as the reference medicine Neulasta.
CHMP je izrazio zabrinutost zbog toga što rezultati ispitivanja nisu pokazali da tijelo podnosi lijek Efgratin na isti način kao i referentni lijek Neulasta.
Therefore, at the time of the withdrawal, the CHMP was of the opinion that the company had not demonstrated that Efgratin is highly similar to Neulasta.
Sukladno navedenome, CHMP je u vrijeme povlačenja smatrao da tvrtka nije dokazala da je lijek Efgratin vrlo sličan lijeku Neulasta.
Efgratin was to be used in cancer patients to reduce neutropenia (low levels of neutrophils).
Lijek Efgratin trebao se primjenjivati u bolesnika oboljelih od raka radi smanjenja neutropenije (niske razine neutrofila).
Filgrastim is very similar to a human protein called
Filgrastim je vrlo sličan ljudskom proteinu koji se naziva faktor stimulacije kolonije granulocita (G-CSF).
The full EPAR for Abraxane can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjeloviti EPAR za lijek Abraxane nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
‘Metastatic' means that the cancer has spread to other parts of the body.
"Metastatski" znači da se rak proširio na druge dijelove tijela;
The main measure of effectiveness was the number of patients who ‘responded' after at least five weeks of treatment.
Osnovna mjera djelotvornosti bio je broj bolesnica koje su "odgovorile na liječenje" nakon barem pet tjedana terapije.
A response was defined as the patient's main tumours disappearing or shrinking in size by at least 30%.
Taj je odgovor definiran kao nestanak osnovnog tumora bolesnica ili njegovo smanjenje za barem 30%.
Abraxane is used to treat the following cancers in adults:
Abraxane se koristi za liječenje sljedećih vrsta raka u odraslih:
Abraxane is given into a vein over a period of 30 minutes.
Abraxane se daje u venu u razdoblju od 30 minuta.
Paclitaxel has been available as a cancer medicine since 1993.
Paklitaksel se koristi kao lijek protiv raka od 1993.
The recommended dose is 125 mg per square metre of body surface area once a day on days 1, 8 and 15 of each cycle.
Preporučena doza je 125 mg po kvadratnom metru tjelesne površine jednom na dan, 1., 8. i 15. dana svakog ciklusa.
It should not be interchanged with other medicines containing paclitaxel.
Ne smije se naizmjence koristiti s drugim lijekovima koji sadrže paklitaksel.
The European Commission granted a marketing authorisation valid throughout the European Union for Abraxane on 11 January 2008.
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Abraxane na snazi u Europskoj uniji od 11. siječnja 2008.
The most common important side effects with Abraxane (seen in more than 1 patient in 10) are neutropenia (low levels of neutrophils, a type of white blood cells), gastrointestinal disorders (disorders of the digestive system), peripheral neuropathy (nerve damage including damage to the nerves in the hand and feet), arthralgia (joint pain) and myalgia (muscle pain).
Najčešće važne nuspojave lijeka Abraxane (kod više od 1 na 10 bolesnika) bile su neutropenija (niske razine neutrofila, vrste bijelih krvnih stanica), gastrointestinalni poremećaji (poremećaji probavnog sustava), periferna neuropatija (oštećenja živaca, uključujući oštećenja živaca dlanova i stopala), antralgija (bol u zglobovima) i mijalgija (bol u mišićima).
The recommended dose is 260 mg per square metre of body surface area (calculated using the patient's height and weight).
Preporučena doza iznosi 260 mg po kvadratnom metru tjelesne površine (izračunato temeljem visine i tjelesne težine bolesnika).
This document is a summary of the European Public Assessment Report (EPAR) for Abraxane.
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek Abraxane.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Abraxane.
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet i svoje preporuke za korištenje lijeka Abraxane.
Around half of the patients in the study had already received treatments for their cancer after it had become metastatic.
Oko polovice bolesnica u studiji već se liječilo od te vrste raka prije nego što je metastazirao.
Therefore, the company withdrew its application for the use of Abraxane as firstline treatment during the assessment of the medicine.
Stoga je tvrtka povukla svoj zahtjev za primjenu lijeka Abraxane u primarnoj terapiji tijekom procjene lijeka.
What measures are being taken to ensure the safe and effective use of Abraxane?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Abraxane?
When looking only at the patients who were receiving their first treatment for metastatic breast cancer, there was no difference between the medicines in terms of measures of effectiveness such as the time until the disease got worse and survival.
Kod analize samo onih bolesnika koji su primili prvu terapiju za metastatski rak dojke, nije bilo razlika između lijekova u smislu mjera djelotvornosti u pogledu vremena u kojem se bolest pogoršala, i preživljenja.
Other information about Abraxane
Ostale informacije o lijeku Abraxane
Paclitaxel blocks a stage of cell division in which the cell's internal ‘skeleton' is dismantled to allow the cell to divide.
Paklitaksel blokira stadij podjele stanice, pri čemu se unutarnji "kostur" stanice onesposobi, što omogućava podjelu stanice.
Abraxane also affects non-cancer cells such as blood and nerve cells, which can cause side effects.
Abraxane također djeluje na stanice koje nisu stanice raka, poput stanica krvi i živaca, što može izazvati nuspojave.
By keeping this structure intact the cells cannot divide and they eventually die.
Održavanjem takve strukture stanice nepromijenjenom, stanice se ne mogu dijeliti te s vremenom odumru.
Patients survived for around 8.5 months on treatment with the combination of Abraxane and gemcitabine, compared with 6.7 months on gemcitabine alone.
Bolesnici su preživjeli oko 8,5 mjeseci na terapiji s kombinacijom lijeka Abraxane i gemcitabin u usporedbi s 6,7 mjeseci na terapiji samo gemcitabinom.
For more information about treatment with Abraxane, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Više informacija o terapiji lijekom Abraxane pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
The main measure of effectiveness was the percentage of patients who responded to treatment.
Osnovna mjera djelotvornosti bio je broj bolesnika koji su odgovorili na liječenje.
Why has Abraxane been approved?
Zašto je Abraxane odobren?
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Abraxane, including the appropriate precautions to be followed by healthcare professionals and patients.
Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi za lijek Abraxane nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
In non-small cell lung cancer, 33% of patients receiving Abraxane and carboplatin responded to treatment compared with 25% of those receiving conventional paclitaxel and carboplatin.
Kod raka nemalih stanica pluća, 33% bolesnika koji su primili Abraxane i karboplatin odgovorilo je na liječenje u usporedbi s 25% bolesnika koji su primili konvencionalni paklitaksel i karboplatin.
Abraxane is a powder that is made up into a suspension for infusion (drip) into a vein.
Abraxane je prašak od kojeg se radi otopina za infuziju (drip u venu).
What is Abraxane?
Što je Abraxane?
• metastatic adenocarcinoma of the pancreas, as a first treatment in combination with another cancer medicine, gemcitabine.
• metastatskog adenokarcinoma gušterače kao prva terapija u kombinaciji s drugim lijekom protiv raka, gemcitabinom;
The main measure of effectiveness was how long patients lived.
Osnovna mjera djelotvornosti bio je životni vijek bolesnika.
For metastatic breast cancer, Abraxane has been studied in one main study involving 460 women, around three-quarters of whom had received an anthracycline in the past.
Kod metastatskog raka dojke, Abraxane je ispitivan u jednom glavnom ispitivanju koje je uključivalo 460 žena, od kojih je oko tri četvrtine prethodno primilo antraciklin.
In non-small cell lung cancer, treatment is carried out in 3-week cycles with Abraxane given on days 1, 8 and 15 of each cycle and carboplatin given on day 1 immediately after Abraxane.
Kod raka nemalih stanica pluća, terapija se provodi u ciklusima od tri tjedna, tako što se Abraxane primjenjuje 1., 8. i 15. dana svakog ciklusa, a karboplatin se primjenjuje na dan neposredno nakon primjene lijeka Abraxane.
What is the risk associated with Abraxane?
Koji su rizici povezani s lijekom Abraxane?
• non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin when the patient cannot have surgery or radiotherapy.
• raka nemalih stanica pluća, kao prva terapija u kombinaciji s lijekom protiv raka karboplatinom kad bolesnik ne može na operaciju niti na radioterapiju.
Immediately after giving Abraxane gemcitabine should be given at a dose of 1000 mg per square metre of body surface area.
Odmah nakon primjene lijeka Abraxane, mora se primijeniti gemcitabin u dozi od 1000 mg po kvadratnom metru tjelesne površine.
The Committee decided that Abraxane's benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor je odlučio da koristi od lijeka Abraxane nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
In metastatic breast cancer, Abraxane was more effective than conventional paclitaxel-containing medicines.
Kod metastatskog rak dojke, Abraxane je bio djelotvorniji od konvencionalnih lijekova koji sadrže paklitaksel.
The CHMP noted that Abraxane was more effective than conventional paclitaxel-containing medicines in patients with metastatic breast cancer whose first treatment had stopped working, and that, unlike other paclitaxel-containing medicines, patients to be treated with Abraxane do not need pre-treatment with other medicines to prevent hypersensitivity reactions.
CHMP je utvrdio da je Abraxane djelotvorniji od konvencionalnih lijekova koji sadrže paklitaksel kod bolesnika s metastatskim rakom dojke, kod kojih prva terapija više nije bila djelotvorna, te da za razliku od drugih lijekova koji sadrže paklitaksel, bolesnicima na terapiji lijekom Abraxane nije potrebna predterapija drugim lijekovima za sprječavanje reakcija preosjetljivosti.
It contains the active substance paclitaxel attached to a human protein called albumin.
Sadrži aktivnu tvar paklitaksel vezanu za ljudsku bjelančevinu naziva albumin.
A risk management plan has been developed to ensure that Abraxane is used as safely and effectively as possible.
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Abraxane.
Abraxane must not be used in patients who are breast-feeding or who have low levels of neutrophils in the blood before starting treatment.
Abraxane se ne smije davati bolesnicama koje doje niti bolesnicima s niskim razinama neutrofila u krvi prije početka terapije.
For non-small cell lung cancer, the Abraxane-carboplatin combination was compared with a combination of a conventional paclitaxel-containing medicine and carboplatin in 1,052 patients.
Kod raka nemalih stanica pluća, kombinacija Abraxane-karboplatin uspoređena je s kombinacijom konvencionalnog lijeka koji sadrži paklitaksel i karboplatin u 1 052 bolesnika.
Abraxane should only be given under the supervision of a specialist cancer doctor in units that are specialised in giving ‘cytotoxic' (cell-killing) medicines.
Abraxane se može primijeniti samo uz nadzor liječnika specijaliste za rak, u specijaliziranim jedinicama za primjenu citotoksičnih lijekova (lijekova kojima se ubija stanice).
In Abraxane, unlike conventional paclitaxel-containing medicines, the paclitaxel is attached to a human protein called albumin in tiny particles known as ‘nanoparticles'.
Za razliku od konvencionalnih lijekova koji sadrže paklitaksel, u Abraxaneu se paklitaksel veže na ljudsku bjelančevinu naziva albumin u sitnim česticama koje se zovu nanočestice.
The active substance in Abraxane, paclitaxel, belongs to the group of cancer medicines known as the ‘taxanes'.
Djelatna tvar lijeka Abraxane, paklitaksel, spada u skupinu lijekova protiv raka pod nazivom "taksani".